# Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

> **NCT00273936** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 72 (estimated)

## Conditions studied

- Acute Leukemia
- Chronic Leukemia
- Multiple Myeloma
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** AVN-944 capsules for oral administration

## Key facts

- **NCT ID:** NCT00273936
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2011-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00273936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00273936, "Trial of AVN-944 in Patients With Advanced Hematologic Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00273936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*